C12N 2501/82
Histamine
C12N2501/82 (Histamine) appears on 14 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 12
- Assignees
- 6
- Inventors
- 19
- Latest grant
- 24 Oct 2017
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 9 |
| 2003 | 0 | 0 |
| 2004 | 2 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Method for generating pancreatic hormone-producing cells24 Oct 2017US 9,796,962 B2Kyoto University
- Treating tumors using implants comprising combinations of allogeneic cells22 Apr 2008US 7,361,332 B2The Regents of the University of California
- Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy13 Feb 2007US 7,175,839 B1Meyer Pharmaceuticals LLC
- Methods and compositions for promoting the maturation of monocytes17 May 2005US 6,893,633 B2Maxim Pharmaceuticals, Inc.
- Methods and compositions for promoting the maturation of monocytes23 Nov 2004US 6,821,510 B2Maxim Pharmaceuticals, Inc.
- Method for generating pancreatic hormone-producing cells6 Oct 2016US 2016/0289642 A1Kyoto University
- Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells11 Sep 2008US 2008/0220025 A1
- Antigen presenting cells, a process for preparing the same and their use as cellular vaccines19 Dec 2002US 2002/0192192 A1I.D.M. Immuno-Designed
- Antigen presenting cells, a process for preparing the same and their use as cellular vaccines19 Dec 2002US 2002/0192193 A1I.D.M. Immuno-Designed
- Methods and compositions for promoting the maturation of monocytes5 Dec 2002US 2002/0182174 A1Maxim Pharmaceuticals, Inc.
Most cited
By later US patents
- Ex vivo activation of immune cells42US 5,766,920 ACellcor, Inc. · 1998
- Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine24US 5,192,537 ACellcor, Inc. · 1993
- Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor16US 6,063,373 AMaxim Pharmaceuticals, Inc. · 2000
- Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy13US 7,175,839 B1Meyer Pharmaceuticals LLC · 2007
- Treating tumors using implants comprising combinations of allogeneic cells8US 6,203,787 B1The Regents of the University of California · 2001